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Abstract
Introduction—Presence of cerebrovascular pathology may increase the risk of clinical diagnosis 
of AD.
Methods—We examined excess risk of incident clinical diagnosis of AD (probable and possible 
AD) posed by the presence of lacunes and large infarcts beyond AD pathology using data from the 
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Statistical Modelling of Aging and Risk of Transition (SMART) study, a consortium of 
longitudinal cohort studies with over 2000 autopsies. We created six mutually exclusive pathology 
patterns combining three levels of AD pathology (low, moderate or high AD pathology) and two 
levels of vascular pathology (without lacunes and large infarcts or with lacunes and/or large 
infarcts).
Results—The coexistence of lacunes and large infarcts results in higher likelihood of clinical 
diagnosis of AD only when AD pathology burden is low.
Discussion—Our results reinforce the diagnostic importance of AD pathology in clinical AD. 
Further harmonization of assessment approaches for vascular pathologies is required.
Keywords
Alzheimer’s disease pathology; vascular pathology; SMART consortium; Population Attributable 
Risk %
BACKGROUND
Epidemiological studies have shown that reducing vascular risk factors could yield large 
decreases in the prevalence of all-cause dementia [1, 2] as well as Alzheimer’s disease (AD) 
[3, 4]. Studies have also shown the significance of vascular disease in the pathogenesis of 
AD [5-10] and that comorbid cerebrovascular pathology plays a key role for clinical 
expression of dementia, especially among the oldest old [11, 12] where mixed pathology is 
common [13, 14]. Self-reported vascular disease or its risk factors used in most 
epidemiological studies give important information regarding the potential contribution of 
these factors on risk of receiving a clinical diagnosis of probable or possible AD (henceforth 
“clinical AD” in this paper), but a more precise assessment of etiology and factors 
associated with clinical AD may be provided by autopsy confirmed evidence. However, it is 
often difficult to obtain a large enough pre-morbidly characterized post mortem sample to 
allow examination of the magnitude of additional risks for clinical AD posed by coexisting 
vascular factors, especially among non-clinical cohorts. In this study, we used the Statistical 
Modelling of Aging and Risk of Transition (SMART) study, which is a consortium of high-
quality longitudinal studies of aging and cognition, established for the purpose of 
characterizing risk and protective factors associated with subtypes of age-associated mixed 
neuropathologies [15]. Our aim was to quantify the excess risk of receiving a clinical AD 
diagnosis associated with the pathology-confirmed presence of lacunes (small artery 
infarcts) and one or more large artery cerebral infarct(s), beyond AD signature pathology 
defined by neuritic plaques scores [16] and Braak & Braak neurofibrillary tangle (NFT) 
stage [17]. We created six mutually exclusive pathology patterns: (1) Low AD pathology 
without lacunes and large infarcts, (2) Low AD pathology with lacunes and/or large infarcts, 
(3) Moderate AD pathology without lacunes and large infarcts, (4) Moderate AD pathology 
with lacunes and/or large infarcts, (5) High AD pathology without lacunes and large infarcts, 
and (6) High AD pathology with lacunes and/or large infarcts. The aim of this study is not to 
delineate the causal relationship between cerebrovascular factors and the development of 
hallmark AD pathologies, but rather to assess the Population Attributable Risk % (PAR%) of 
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lacunes and large infarcts on having clinical AD, i.e., the proportion of clinical AD 
incidence that could be eliminated by preventing lacunes and large infarcts.
METHODS
Participants
The SMART data consortium and the longitudinal cohort studies included in the data set are 
explained in detail elsewhere [15]. Based on the availability of necessary variables, 
participants from the following 8 projects contributed by 4 centers in the USA were included 
in the present study: the Oregon Brain Aging Study I and II [18], the African American 
Dementia Project [15], and the Klamath Exceptional Aging Project [19] from Oregon Health 
& Science University, Portland, Oregon; the Religious Orders Study [20] and the Rush 
Memory and Aging Project [21] from the Rush University, Chicago, Illinois; the Memory 
and Aging Project [22] from Washington University, St Louis, Missouri; and the 
Biologically Resilient Adults in Neurological Studies [23] from University of Kentucky, 
Lexington, Kentucky. We note that these four centers are Alzheimer’s Disease Centers 
(ADCs), although the cohorts mentioned above are recruited from communities. Institutional 
Review Boards at each research center approved all study procedures, and all participants 
provided written informed consent.
Harmonization of variables
SMART investigators reviewed data collection protocols from each participating center and 
identified elements that were common to at least two centers. Data templates, based on the 
methods established by the National Alzheimer’s Coordinating Center (NACC) [24], which 
aggregates data collected by ADCs, were developed to request standardized data elements 
from each center. Data templates for demographic information, genetics and family history 
of dementia, clinical diagnosis, motor function, medical history, medication use, physical 
examination, and neuropathology were the same for all centers. All centers used similar 
criteria for diagnoses of all-cause dementia (DSM-III-R [25]or DSM-IV[26]) and clinical 
AD [27]. However, clinical diagnoses of mild cognitive impairment (MCI) were less 
standardized because some studies were initiated before MCI diagnostic criteria were 
established, and MCI diagnostic criteria have evolved over time. Therefore, in the current 
study, we are limiting our outcome of interest to AD, not MCI or MCI due to AD.
Pathology variables
Neuropathological assessments were performed blind to clinical data. The component 
neuropathological data were coded according to NACC guidelines, as described previously 
(see https://www.alz.washington.edu/nonmember/np/rdd_np.pdf). We created six mutually 
exclusive pathology patterns: (1) Low AD pathology without lacunes and large infarcts, (2) 
Low AD pathology with lacunes and/or large infarcts, (3) Moderate AD pathology without 
lacunes and large infarcts, (4) Moderate AD pathology with lacunes and/or large infarcts, (5) 
High AD pathology without lacunes and large infarcts, and (6) High AD pathology with 
lacunes and/or large infarcts. We used the Consortium to Establish a Registry in Alzheimer’s 
Disease [CERAD] neuritic plaque rating [16] and Braak & Braak NFT stages [17] to define 
low, moderate and high AD pathology. Low AD pathology was defined as Braak NFT stage 
Dodge et al. Page 3
Alzheimers Dement. Author manuscript; available in PMC 2018 June 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
of none, stage I or II with CERAD plaque stage of none or sparse; high AD pathology was 
defined as Braak NFT stage V or VI with CERAD plaque stage of moderate or frequent. 
Moderate AD pathology was defined as those cases falling between the low and high groups 
(details shown in Table 2, discussed later). Large infarcts were defined as those with 
maximum diameter greater than 1 cm that were territorial in nature and attributed to 
compromise involving large- or medium-sized meningocerebral vessels; lacunes were 
defined as infarcts or hemorrhages 1 cm or less in diameter due to small parenchymal 
vascular disease and most commonly encountered in the deep gray matter.
Covariates
Participant age at death (centered at 85 years), sex (female=1, male=0), years of education, 
APOE-ε4 carrier status (at least oneAPOE-ε4 allele=1, no APOE-ε4 alleles=0), Lewy body 
pathology presence (yes=1, no=0), and indicators for center (Rush, Kentucky, Washington 
University, with Oregon as the reference group) were considered.
Statistical Analyses
We examined characteristics associated with having an autopsy (i.e., autopsy data not 
missing) to assess possible selection bias. Group differences (with or without autopsy) were 
examined first by univariate analysis using Student’s t-test or Wilcoxon ranked sum test for 
continuous variables and the Pearson chi-square test for categorical variables, and then by 
multivariate analysis using a logistic regression model with the outcome being presence or 
absence of autopsy data. The risks of developing a clinical diagnosis of AD associated with 
the six pathology patterns were examined using a Cox proportional hazards model with age 
as the time scale. To examine variability across centers, we ran the models with (model 1) 
and without (model 2) center indicators. Proportionality assumptions were examined 
through visual inspection of log-log survival curves, and analytical assessments [28] using 
covariates-by-time interactions in the Cox model. Using the coefficients obtained from the 
models and prevalence of each of the six pathology patterns, we estimated the Population 
Attributable Risk % (PAR%). PAR% is determined by both the prevalence of a risk factor 
and the magnitude of its effect.
Sensitivity analysis using multiple imputation approaches
As a sensitivity analysis, we imputed missing pathology data using multiple imputation 
approaches and examined whether conclusions differed if we used the imputed data. 
Preliminary analyses showed that missingness among pathology data was dependent on 
observed data, and therefore we assumed that our data were missing at random (MAR [29]). 
In order to increase precision of imputed pathology patterns, we also imputed age of onset of 
dementia and clinical AD, if these data were missing. There were several challenges to our 
imputation approaches including: (1) missingness occurred in multiple different types of 
variables, including binary (yes/no) and continuous (ex: age of onset) variables, (2) there 
were boundary restrictions, e.g., age of clinical AD onset must occur later than the last 
observed date when a clinical diagnosis of normal cognition was provided, and (3) there 
were logical restrictions, e.g., clinical AD onset could be imputed only if participants had 
dementia onset (either imputed or actually observed). Therefore, we applied a sequential 
regression multiple imputation approach (SRMI)[30-32]), also known as multivariate 
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imputation by chained equations (MICE, [33]), to impute these missing values. Briefly, the 
SRMI approach uses an iterative algorithm with a sequence of fully conditionally specified 
models. It’s particularly useful in our study as SRMI can easily handle the challenges 
mentioned above. The following variables were used in SRMI: completely observed 
variables (without missing data) used for imputation included gender, education, age at 
death, clinical diagnosis at last clinical assessment before death, duration of follow-up, 
duration between the last clinical assessment and death, center indicators and APOE-ε4 
information. Variables imputed sequentially included age at dementia onset, age at AD onset 
and pathology variables (Braak and CERAD scores, Lewy body pathology, lacunes and large 
infarcts). We closely monitored algorithm convergence as reported in Results. All analyses 
were conducted using statistical software R (version 3.1.3) and SAS 9.3® (SAS Institute, 
Inc., Cary, NC).
RESULTS
Out of 5405 participants with intact cognition at baseline, 1673 participants died (Figure 1). 
Among them, 1566 participants had APOE information. Among them, 1054 participants had 
an autopsy with complete pathology information and were used in the primary analyses. An 
additional 512 participants with none or missing autopsy variables (Figure 1) were also used 
for our sensitivity analysis where we imputed autopsy data. The mean (standard deviation, 
range) baseline age of the full sample (n=1566 participants) was 79.7 years (7.2, 59.5 – 
101.9), mean age at death was 88.5 years (7.2, 61.6 – 107.9), and 54.4% were women. 
Average observed duration of follow-up to death was 8.5 years (5.0) and average time from 
the last assessment to death was 1.6 years (2.1). Table 1 shows the characteristics of the 
participants with and without autopsy based on univariate analyses. Those without autopsy 
were older (p=0.01), more likely to be white (vs. non-white) (p<0.001), lower years of 
education (p<0.001), had shorter duration of follow-up (p=0.006), and longer duration 
between the last clinical assessment to death (p<0.001).
Table 2 shows the prevalence of the six pathology patterns, frequency of the NFT and plaque 
categories by pathology patterns, observed number of clinical diagnoses of AD and vascular 
dementia, presence of Lewy body pathology, and the prevalence of APOE-ε4 allele 
(proportion of subjects with at least one ε4 allele) by the six pathology patterns. Moderate 
AD pathology (58%) was the dominant pattern. We also provided separate columns for: (a) 
neocortical Lewy body pathology [34, 35] and (b) primary age-related tauopathy, or PART 
[36], which was defined here as CERAD plaque stage of none or sparse with Braak stage of 
III or above, due to the tendency of these pathologies to mimic the clinical symptoms of AD. 
About 23% of subjects in this study (245 of 1054) had a clinical AD diagnosis during follow 
up, and 6% (60 of 1054) were diagnosed with probable or possible vascular dementia. Lewy 
body pathology was seen among 19% of the participants (204 of 1054), and among them 
44.6% (91 of 204) had neocortical Lewy body disease. Neocortical Lewy body disease 
among those with clinical AD was rare when the AD pathology rating was low but was seen 
in about 20% of subjects with clinical AD when the AD pathology rating was moderate or 
severe. PART accounted for 13.5% (33 of 245) of clinical AD cases. APOE-ε4 prevalence 
increased as the level of AD pathological burden increased: 12% among those with low AD 
pathology, 20% among those with moderate AD pathology, 36% among those with high AD 
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pathology without lacunes and large infarcts, and 49% among those with high AD pathology 
with lacunes and/or large infarcts. As expected, incident clinical AD was more likely to have 
occurred among those with high AD pathology, with over 50% of those with high AD 
pathology diagnosed with clinical AD during the follow-up.
Table 3 shows the logistic regression results for the factors associated with missing autopsy 
data. Older age at death, white race, and higher education were associated with lower 
likelihood of missing autopsy, while longer duration from the last observation to death was a 
positive predictor of missing autopsy, confirming that the MAR assumption was reasonable 
in our data, although we cannot exclude the possibility that the missing data pattern was 
nonignorable (i.e., informative dropout).
Main results
Education, sex, presence of APOE-ε4 and Lewy body pathology were controlled for in 
Model 1 with age as the time scale, and we further added center indicators in Model 2 (Table 
4). For each AD pathology level (low, moderate and high), we assessed whether having 
lacunes and/or large infarcts posed an excess risk of a clinical diagnosis of AD by comparing 
the hazard rate for AD pathology only with that for AD pathology with vascular factors. In 
Model 1, all other pathology patterns showed a higher risk of being diagnosed with clinical 
AD in comparison with low AD pathology without lacunes and large infarcts (reference 
group), with adjusted hazard ratios (HR) ranging from 2.6 (moderate AD pathology without 
lacunes and large infarcts) to 8.6 (high AD pathology without lacunes and large infarcts). 
The additional risk posed by lacunes or large infarcts was significant among those with low 
AD pathology (p=0.017) and moderate AD pathology (p=0.018), but was not significant 
among those with high AD pathology (p=0.199), suggesting that once AD pathology 
becomes definitive, having lacunes or large infarcts does not add to the risk of being 
diagnosed with clinical AD. In Model 2, controlling for center effects attenuated the 
additional risks posed by lacunes and large infarcts. We found an additional risk posed by 
these vascular factors only among those with low AD (p=0.012). Regarding the center 
effects, significant variability was found across centers: in comparison with Oregon cohorts 
(the reference group), the Rush cohort showed a higher likelihood of having incident clinical 
AD diagnosis (HR=1.73, p<0.01), while the Washington University cohort showed a lower 
likelihood (HR=0.27, p<0.01). The Kentucky and Oregon cohorts were similar regarding the 
risk of incident clinical AD diagnosis. Regarding other covariates, Lewy body pathology 
was consistently significantly associated with an increased risk of clinical AD regardless of 
models or with/without imputation with an HR of 1.5. Finally we calculated PAR% using 
the coefficients derived from Table 4 Model 2, and the prevalence of pathology types 
reported in Table 2. PAR% ranged from 14% (low AD pathology with lacunes and/or large 
infarcts) to 45% (high AD pathology without lacunes and large infarcts). Overall, an 
estimated 89% of clinical AD could be eliminated by preventing all five AD pathology 
patterns (patterns from (2) to (6)). Additionally, 9.5% of clinical AD could be eliminated by 
preventing Lewy body pathology. Excess risk of clinical AD posed by vascular factors was 
only significant among the low AD pathology group: the proportion of clinical AD 
attributable to lacunes or large infarcts was estimated as 14.3% or less.
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Sensitivity analysis using imputed data
To address potential selection bias from using only autopsied participants, we also imputed 
pathology types in a sensitivity analysis. The results are listed in Table 4. The imputation did 
not yield any notable changes to the main results reported in Model 2; again additional HRs 
(excess risk) associated with lacunes and/or large infarcts were only significant among those 
with low AD pathology (p=0.02). Using the imputed pathologies, the center effect of 
Washington University became insignificant, i.e., their participants’ risk of incident clinical 
AD was similar to Oregon’s.
Post-hoc analyses
The six pathology patterns used in the study were based on 1991 criteria of Braak and Braak 
[17]. Braak et al. modified the criteria for the use of immunohistochemistry [37]; the 
modified criteria were tested in a large European multicenter study, and it was concluded 
that at least moderate severity of neuropil threads/NFTs is needed to count an area positive 
for most Braak stages [38]. Therefore, we limited these analyses to cases autopsied after 
January of 2006 and examined what proportion of those cases with high AD pathology with 
or without lacunes and large infarcts had clinical diagnosis of AD. Out of 104 cases with 
high AD pathology (pathology patterns (5) and (6) defined here), 73% (n=76) had diagnosis 
of clinical AD and additional 13% (n=14) had other types of dementia (vascular, Dementia 
with Lewy bodies, and frontotemporal dementia). Cox proportional hazard models were also 
run using only subjects autopsied after 2006. The results are included in Supplemental Table 
1. The HRs for AD pathology increased in magnitude, indicating closer correspondence 
between AD pathology and clinical diagnosis of AD. The results regarding contribution of 
lacunes and large infarcts remained unchanged.
To delineate further the effect of vascular factors on clinical dementia incidence, we ran an 
additional model with the outcome of overall dementia using observed data (Table 5). 
Lacunes and large infarcts posed excess risk among those with low AD pathology (p=0.01) 
as well as those with moderate AD pathology (p=0.04). The HRs ranged from 1.81 
(moderate AD pathology without lacunes or large infarcts) to 6.11 (high AD pathology 
without lacunes or large infarcts). Up to 34% of overall dementia could be eliminated by 
preventing lacunes and large infarcts based on the PAR% using HRs for which the vascular 
contribution was shown to be significant. Combined PAR% showed that about 74% of 
overall clinical dementia could be eliminated by preventing AD pathology patterns 
examined here, and an additional 10% could be eliminated by preventing Lewy body 
pathology.
DISCUSSION
There is growing interest in the influence of vascular factors on clinical AD incidence 
[3-12]. Using harmonized pathology data derived from well-characterized community 
cohorts followed at ADCs in the United States, we assessed whether coexistence of vascular 
factors posed additional risk of an incident clinical diagnosis of AD beyond the risk 
associated with AD pathology, and to what extent clinical diagnosis of AD could be 
prevented by eliminating lacunes and large infarcts. There are several noteworthy findings.
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First, the prevalence of clinically diagnosed AD increased as the severity of AD pathology 
increased from 4.2% (among low AD pathology group) to 53.3% (among high AD 
pathology group), showing high correlations of plaques and tangles with overall clinical AD 
incidence. Yet about half of the participants died without clinical AD diagnosis, despite 
having high AD pathology. This result coincides with previous studies among community 
samples [14] [39], showing between one-third and one-half of community samples may die 
without having a clinical AD diagnosis, despite autopsy findings of moderate or high AD 
pathology. Ours and these latter studies are based on 1991 Braak criteria [17]. Limiting the 
samples to those autopsied after 2006 , i.e., the cases likely assessed based on newer criteria 
[37], we found a higher proportion (73%) of those with high AD pathology had clinical 
diagnosis of AD. This proportion is still lower than those found among clinical samples [40]. 
This discrepancy may be due, in part, to the fact that some cases after 2006 were still 
measured by the older Braak criteria. It is also possible that our study subjects were drawn 
from highly educated and healthy volunteers who likely had increased cognitive reserve 
relative to clinical samples. Additionally, informants were not always available in the 
community samples, which might have led to an underestimation of cognitive problems. All 
explanations are limited to speculations at this point.
One important question is whether these participants with moderate and high AD pathology 
would have been diagnosed with clinical AD during their lifetime, had they lived longer. In 
our imputed data, we found that 40.8% of those with moderate or high AD pathology 
without an observed diagnosis of clinical AD or dementia had an imputed age of AD onset 
within three years after their date of death. In other words, we estimated that 40% of 
participants who died without a clinical AD diagnosis, despite having moderate or high AD 
pathology, would have been diagnosed if they had lived longer. If life expectancy among the 
oldest old age group increases, the prevalence of AD could increase sharply unless advances 
in the prevention and treatment of AD are also made. Regarding the PAR%, an estimated 
89% of incident clinical AD cases could be prevented by eliminating AD pathology, either 
alone or in combination with lacunar and large infarcts. The PAR% estimates of the 
moderate and high AD pathology groups were similar due to higher prevalence of those with 
moderate AD pathology despite their lower hazard of clinical AD. Regarding overall 
dementia (i.e., including all sub-types of dementia), 75% of incident cases could be 
prevented by eliminating AD pathology. We expect the contribution of vascular factors on 
vascular dementia incidence is large, but our small sample size precluded us from estimating 
HRs using vascular dementia as the outcome.
Second, in the harmonized data used in this study, the mean age at death was about 90 years 
old, and the excessl risk of clinical AD posed by the coexistence of lacunes and large 
infarcts was relatively small; a significant contribution was only observed among those with 
low AD pathology. It is well established that the prevalence of mixed dementia increases as 
age increases [5, 12, 13, 41-43]. However, we found having AD pathology without lacunes 
and large infarcts was more prevalent in the participants examined here, with 60% having 
AD pathology (combining low, moderate and high) without lacunes or large infarcts in 
comparison to 40% with these vascular factors. Meta-analyses of epidemiological studies 
have shown that vascular diseases and vascular disease risk factors in midlife are risk factors 
of AD in later life [1, 2, 4]. Clinical expression of AD could be promoted via cardio- and 
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cerebrovascular diseases, possibly due to reduced cognitive reserve, but the vascular and AD 
pathological developments could be independent [44-46], although the latter has not been 
proven. Our results support previous findings [47, 48] that reinforced the diagnostic 
importance of AD pathology in clinical AD, as well as a more recent finding among those 
aged 90 years and older [49]. It is possible that clinicians tend to give a diagnosis of possible 
vascular dementia if they see lacunes and especially large infarcts on neuroimaging, which 
may underestimate the vascular contribution of clinical AD. Incidence of vascular dementia 
in our data was relatively low (about 12% out of those diagnosed with any dementia were 
diagnosed with vascular dementia), limiting the overall contribution of lacunes and large 
infarcts at population level. Our finding that the significant additional risk posed by lacunes 
and large infarcts occurred only among those with low AD pathology also confirms earlier 
findings by Boyle et al. (e.g., Figure 3 in [50]) and Schneider et al. (Figure 1 and 2 in [51]), 
where the authors found that the variability of cognitive decline explained by vascular 
factors was more prominent when the severity of AD pathologies was lower. If the presence 
of vascular pathology promotes the accumulation of AD pathology [52, 53], then the 
underlying contribution of vascular factors on overall AD incidence is much higher. 
However, this causal relation cannot be ascertained using our dataset since autopsy data 
cannot provide the time order of pathological events. One notable limitation in our analysis 
is that we did not examine micro-infarcts [54] due to the necessity to harmonize data across 
sites, which could have led to an underestimation of the prevalence of vascular factors. 
Further harmonization of assessment approaches for micro-infarcts and other vascular 
markers in our data could address this issue in the future [54].
Third, about 15% (n=167) of participants had low AD pathology without lacunes or large 
infarcts, and among them 21 (2% of the total) were found to have no NFTs and no neuritic 
plaques (data not shown), confirming that even among our participants, who had a mean age 
at death of 90 years old, it was possible, if rare, to remain free from these pathologies. 
Comparing these participants with others regarding their genetic, premorbid neuroimaging 
and other biomarker results could reveal some key factors relating to aging free from AD 
pathological development.
Fourth, we found significant center effects. The cohorts followed by Rush University 
(located in Chicago, IL, USA) had a higher hazard of diagnosed AD compared with the 
cohorts followed in Oregon (located in Portland, OR, USA) and Kentucky (located in 
Lexington, KY, USA), while the Washington University cohort (located in St. Louis, MO, 
USA) had a lower hazard of incident AD, although the latter was not found when using 
imputed data. These differences were seen after controlling for pathological characteristics, 
i.e., given the same levels of AD pathology, lacunes and large infarcts, Lewy body 
pathology, and APOEε4 contributions. Unlike the diagnosis of MCI, the diagnostic 
procedure of AD is well harmonized across centers, but there may still be some variability 
depending on, for example, whether biomarker information was used in consensus 
diagnoses. The center differences could also be due to differences in susceptibility to AD 
symptoms by cohort, including racial compositions as well as lifestyle factors and 
environment.
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Finally, selection bias in the autopsied group could distort study results. For example, if 
those who die without dementia are less likely to come to autopsy, then this could 
potentially overestimate the association between pathology and AD incidence. In the current 
study, using imputed pathology data did not change the main results. The magnitude of bias 
associated with missing autopsy data is likely to depend on the cohorts examined in the 
study. We advise researchers to conduct sensitivity analyses when analyzing autopsy data to 
examine the potential selection bias.
Limitations of this study include: all cohorts included in this study are community-based, 
but they are not a random sample of the community. Generalizability of the results may be 
limited. Data harmonization requirements excluded some variables from the analyses that 
were found to explain variability in cognitive decline in other papers, including hippocampal 
sclerosis [47, 55, 56], TDP-43 proteinopathy [55-57], microinfarcts [54], cerebral amyloid 
angiopathy [58], and arteriolosclerosis and atherosclerosis [59]. We could not differentiate 
the location of infarcts and its effects on clinical diagnosis of AD. Despite these 
shortcomings, the data used here have the advantage of providing a relatively large sample 
size, adequate longitudinal follow-up, and multicenter data not limited to a specific 
geographic region, which increases generalizability. Continuation and expansion of the 
pathology consortium and improvement of standardized neuropathological assessment 
criteria are strongly encouraged to further advance our understanding of biological 
mechanisms and cognitive functions over time.
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Refer to Web version on PubMed Central for supplementary material.
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Sample Size Flow Chart
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Table 1
Characteristics of participants who died during follow-up with or without autopsy (N=1566)
Parameters With Autopsy
N=1054
Without Autopsy
N=512*
P-value#
Mean (continuous
variable) or N
(categorical
variable)
STD
(continuous
variable) or
%
(categorical
variable)
Mean (continuous
variable) or N
(categorical
variable)
STD (continuous
variable) or
% (categorical
variable)
Age at death, years: mean, std 88.53 7.26 89.49 7.31 0.014
Women: n % 666 63.2 314 61.33 0.48
Race: White % (vs. Non-White) 1039 98.7 469 91.6 <0.001
Education, years: mean, std 15.9 3.43 14.39 3.46 <0.001
APOE (having at least one ε4 allele):
n %
233 22.10 117 22.85 0.74
Duration of follow-up, years:
mean,std
7.84 4.73 6.92 5.14 0.006
Duration between last observation to
death, years: mean, std
0.96 1.29 1.83 2.22 <0.001
Centers: n % <0.001
 Oregon 113 10.72 190 37.11
 Rush 549 52.09 114 22.27
 Washington U 122 11.57 154 30.08
 Kentucky 270 25.62 54 10.55
#
: based on univariate analysis
*
: including a small proportion of subjects (n=77) who had autopsy, but missing some of pathology variables of our interests
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Table 3
Logistic regression model with missing autopsy as the outcome
Parameter (OR unit difference) OR 95% CI p-value
Age at death (1 year) 0.98 0.96 - 1.00 0.02
Female (vs. Male) 0.86 0.67 - 1.11 0.26
Race (White vs. Non-White) 0.26 0.13 - 0.52 <0.01
Education (1 year) 0.95 0.91 - 0.99 <0.01
APOE (having at least one ε4 allele vs
no ε4 allele)
1.10 0.82 - 1.47 0.55
Duration of follow-up (1 year) 0.98 0.96 - 1.01 0.23
Duration from the last observation to
death (1 year)
1.35 1.25 - 1.47 <.0001
Onset of clinical AD observed during
the follow-up (vs. censored)
1.06 0.76 - 1.48 0.73
Center effects were controlled in the model.
The number of subjects who did not have autopsy =435, the number of subjects who had autopsy = 1131 (1054+ 77).
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Table 5
Results of Cox Proportional Hazard Model with Pathology Patterns as Independent Variables with Outcomes 
being Incidence of Overall Dementia
Parameter Using Observed Data Only
Hazard Ratio
(95% CI)
Overall Dementia
Difference
in
Coefficient
p-value
PAR%
Overall Dementia
Female (vs. Male) 0.90 (0.69-1.18)
Education (1 year) 1.02 (0.99-1.06)
APOE ε4 (having at least one
ε4 allele vs no ε4 allele)
1.37 (1.04-1.82)*
Lewy Body Pathology (yes
vs. no)
1.57 (1.21-2.04)** 9.9%
Pathology patterns
  (1) Low AD pathology
    without lacunes and
    large infarcts
Ref
(1) vs(2)
P=0.010*
  (2) Low AD pathology with
    lacunes and/or large
    infarcts
2.77 (1.26-6.10)*
6.1%
  (3) Moderate AD pathology
    without lacunes and
    large infarcts
1.81 (0.92-3.59)
(3) vs (4)
P=0.042*
21.0%
  (4) Moderate AD pathology
    with lacunes and/or
    large infarcts
2.56 (1.30-5.05)**
28.3%
  (5) High AD pathology
    without lacunes and
    large infarcts
6.11 (3.06-12.20)**
(5) vs (6) P=0.678 33.8%
  (6) High AD pathology with
    lacunes and/or large
    infarcts
5.64 (2.78-11.42)**
25.6%
Combined PAR# (pathology
patterns (2), (3), (4), (5) and (6)
listed above)
73.8%
Center Effects:
  Oregon cohorts
Ref
.....Rush 1.48 (1.02-2.15)*
.....Washington U 0.73 (0.44-1.20)
.....Kentucky 0.99 (0.65-1.51)
*
: p<0.05,
**
: p<0.01
PAR% was calculated by using formula: (prevalence × (RR-1))/(1+(prevalence × (RR-1))
#
: Calculated using the formula: 
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